Form 10-12B
We note that your summary appears to discuss primarily the positive aspects of your business. The information statement summary should provide a brief, but balanced, description of the key aspects of your business.Rest of the question
Please revise the summary to also discuss the following points as discussed in the Risk Factors and other sections of the Information Statement: • the fact that you do not currently have coverage and reimbursement from third-party payors, either private or government, for Galleri; • that Galleri has not been approved by the FDA or equivalent foreign regulators and that the process of obtaining a PMA generally takes from one to three years, or even longer, from the time the application is submitted to the FDA; • that while you have a number of clinical studies underway designed to evaluate the clinical validity of Galleri, your product is not yet, and may never be, listed in any guideline recommendations, even if approved by the FDA; • that upon closing of the Spin-Off, your obligation to pay to Illumina a high-single digit royalty will resume, which was suspended while you were owned by Illumina and that it may be difficult for you to offset the costs of this royalty; and • quantify your net losses for the financial periods presented in the filing and your accumulated deficit as of the most recent fiscal period presented in you filing.
No reply letter found.
Please clarify what it means for the Galleri test to be "clinically-validated" and who has made this determination. In this regard, we note that you have not received FDA approval for the Galleri test and your NHS Galleri and PATHFINDER 2 studies are still ongoing.
No reply letter found.
We note certain statements in your information statement that do not appear to be attributed to the company or an outside source. Please provide support for these statements or characterize the same as management's opinions or beliefs.Rest of the question
For example, we note, without limitation, your statements: • on page 2 that "Galleri detects a shared cancer signal across more than 50 types of cancer and can predict with high accuracy the specific organ or tissue type where the cancer signal originated;" • on pages 3 and 19 that you estimate "[a]pproximately 67% of cancer deaths result from cancers that have no recommended screening guidelines;" • on page 3 that "a recent analysis demonstrated that diagnosing cancer early could result in an estimated $26 billion in annual cost-savings in the United States;" • on page 3 that "Galleri predicts the tissue type or organ associated with the cancer signal (the cancer signal origin) with high accuracy;" • on page 3 that "Our clinical studies, including our early discovery work, have demonstrated robust and reproducible test performance;" • on page 3 that you are "an early leader in MCED testing;" • on page 4 that your "targeted methylation approach can detect lower levels of cancer signal in blood compared to the other approaches, enabling early cancer detection in asymptomatic individuals more efficiently compared to whole-genome methylation;" • on page 118 that "It is estimated that the global economic cost of cancer from 2020 to 2050 will be approximately $25 trillion;" • on page 119 that "Treatment costs increase by stage across all cancers, and treating cancers that are in more advanced stages can be up to two to four times more costly than treating cancers at earlier stages;" and • on page 119 that "less common cancers . . . account for a majority of all cancer deaths."
No reply letter found.
As a related matter, we note your disclosure that "Galleri detects a shared cancer signal across more than 50 types of cancer and can predict with high accuracy the specific organ or tissue type where the cancer signal originated, all from a simple blood draw." Please revise these and all similar statements in your registration statement to eliminate conclusions, predictions, or opinions that your product isRest of the question
effective or accurate, whether implicitly or impliedly. We do not object to the presentation of objective data without efficacy or accuracy determinations.
No reply letter found.
We note your statement that "[w]e seek to use data from the NHS-Galleri Trial, together with data from our PATHFINDER 2 study, as well as supplemental data from other clinical studies, to support our planned PMA submission for Galleri in the United States." Here or elsewhere in the Information Statement, please explain why you intend to use data from the NHS-Galleri Trial and PATHFINDER 2 study to support your PMARest of the question
submission rather than relying on data from other studies such as PATHFINDER or CCGA.
No reply letter found.
We note your reference on page 2 to Grade A, B, and C recommendations. Please revise your disclosure to define and describe the significance of these grades. In addition, please clarify your reference to "these five standard of care single-cancer screening tests." Make conforming changes throughout your filing.
No reply letter found.
At the first instance, please define the following terms or provide a cross reference to their definition elsewhere in the filing: methylation, targeted methylation, highly informative and low-noise methylation regions, interrogating mutations, chromosomal alterations, fragment lengths, and other genomic features, and describe their relevance to your statements about your product.Rest of the question
As a related matter, we note your disclosure that "[i]n our head-to-head analyses, methylation exhibited stronger performance when compared to interrogating mutations, chromosomal alterations, fragment lengths, and other genomic features, either alone or in combination." Please revise your disclosure to briefly describe how you measure "performance," and include the relevant data from your head-to-head analyses supporting your belief that targeted methylation exhibited "stronger" performance when compared to other features. Make conforming changes throughout your filing.
No reply letter found.
You disclose that you are developing your diagnostic aid for cancer ("DAC") test to accelerate diagnostic resolution for patients with non-specific signs and symptoms, but with a clinical suspicion of cancer. Please revise your disclosure to describe the status of your development efforts and your expected timeline for the development and commercialization of your DAC test.Rest of the question
As a related matter, we note your reference to "other future products in development." Please identify any other products in development and their relevant status.
No reply letter found.
We note your disclosure that the Illumina Board also considered a number of potentially negative factors in evaluating the Spin-Off. Please revise your disclosure in this section to briefly describe these negative factors.
No reply letter found.
Please revise your risk factor disclosures to include risks related to the regulatory proceedings described on page 96 in the Background of your spin-off transaction and on page F-35 in note 12 to your financial statements, including but not limited to any significant costs incurred or expected to be incurred related to GRAIL's intervention in the proceedings, risks related to the completion of the Separation andRest of the question
Distribution pursuant to the legal proceedings, reputational risk due to news media reports on the relevant regulatory intervention, and any other material risks. Risks Relating to Our Business and Industry We may be unable to develop and commercialize new products, including enhanced versions of current products., page 39
No reply letter found.
We note your statement that you "continue to expand [y]our research and development efforts to use [y]our proprietary methylation platform and [y]our large clinical and genomic datasets to develop enhanced versions of [y]our products and future products." Please briefly explain what changes or improvements you expect to make to the enhanced versions of your current products and if you believe these changes willRest of the question
impact your ability to rely on previously-collected data on earlier versions of your products in connection with your submission for marketing authorization (or certification) of your products. Risks Relating to Regulation and Legal Compliance Our multi-cancer detection tests are a new approach to cancer screening, which present a number of novel and complex issues. . ., page 59
No reply letter found.
We note your statement that "As part of our ongoing discussions with the FDA regarding the data that will be needed to support a PMA for a multi-cancer detection test based on a proposed intended use, the FDA has provided feedback regarding how it plans to assess the safety and effectiveness of our new version of Galleri based on potential intended use statements." Please briefly describe the feedback received fromRest of the question
the FDA and clarify what you mean by the new version of Galleri. Risks Related to Intellectual Property If we are unable to obtain and maintain intellectual property protection for our technology. . .,
No reply letter found.
We note your statement here that "eight of our in-licensed European patents and one of our owned European patents have been subject to oppositions in Europe, as described below." However, we also note your statement on page 79 that you "faced three oppositions in Europe with respect to European patent number EP 3 363 901 B1 inlicensed from the Fred Hutchinson Cancer Center, European patent number EP 3 354 747 B1Rest of the question
in-licensed from The Chinese University of Hong Kong, and European patent number EP 3 478 856 B1 assigned to GRAIL, LLC," and your statement on page 147 that you "are currently facing oppositions from anonymous challengers against two of our inlicensed European patents and one of our owned patents." Please clarify if you received opposition to European patents other than EP 3 363 901 B1, EP 3 354 747 B1 and EP 3 478 856 B1.
No reply letter found.
We note your statements that "neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements" and "you are cautioned not to place undue reliance on such forward-looking statements as predictions of future performance or otherwise." Please revise these statements to remove any implication that investors are not entitled to rely on disclosure in yourRest of the question
registration statement.
No reply letter found.
Please revise your disclosure describing the background of the spin-off transaction in this section to include a discussion of the regulatory proceedings initiated by the US Federal Trade Commission on March 30, 2021, described in Note 12 to your financial statements on page F-35 of your filing.Rest of the question
In your discussion, please clarify whether and to what extent you expect the divestment of GRAIL, including Illumina's retention of the 14.5% ownership interest in GRAIL, to impact these proceedings.
No reply letter found.
You disclose that "[i]n connection with the EC Divestment Decision and with the goal of enhancing stockholder value, the Illumina Board conducted a process through which it considered a range of potential divestment transactions," and "[a]s part of this evaluation, Illumina retained outside advisors, and the Illumina Board considered a number of factors . . .Rest of the question
." To the extent that the board's decision to effect a spin-off was based in material part on the analysis or recommendation of these outside advisors, please identify the outside advisors and discuss the nature of the reports and recommendations provided by them to the Illumina board.
No reply letter found.
Please revise your disclosure to provide additional detail regarding the reasons for Illumina's retention of up to 14.5% of GRAIL common stock, including what is meant by "investment purposes," and advise us of any specific plans Illumina currently has to dispose of such shares.Rest of the question
Disclose whether there is any minimum period of time following the distribution during which Illumina will refrain from distributing its retained shares. In this regard, while your disclosure indicates that there is a maximum period of five years following the distribution to consummate a disposition of the retained equity, your disclosure does not address whether there are any active plans to dispose of such equity shortly after the distribution.
No reply letter found.
Revise your disclosure to clarify whether cancer may be "cured" and if so, please provide a basis for your assertion that early detection results in discovering cancer "when it can be cured." Alternatively, please delete this statement.
No reply letter found.
You disclose that "key results from our interventional PATHFINDER study were generally consistent with data from our case-control CCGA study, which is evidence supporting the generalizability and robustness of Galleri." Please revise your disclosure to expand upon the key results to which you refer, describe what is meant by "generally consistent," and describe the significance of the "generalizability andRest of the question
robustness" of Galleri.
No reply letter found.
You disclose that your targeted methylation approach can detect lower levels of cancer signal in blood compared to other approaches. Please clarify the "other approaches" to which you refer.
No reply letter found.
We note your disclosure in the footnotes to your table that your false positive rate was based on participants with cancer status assessment at the end of your study. To provide investors with additional context needed to understand your data, please clarify the percentage of your study participants who received cancer status assessment at the end of your study, including whether any participants received a positiveRest of the question
result without a status assessment, and therefore could be omitted from your false positive rate.
No reply letter found.
We note your statement that you "established clinical validation using a locked assay and classifier in case-controlled and intended-use populations." Please expand on this statement to explain what locked assay and classifier and case-controlled mean in this context.
No reply letter found.
You disclose that your graphic presents the PPV and number of false positives associated with the current standard of care screening tests. Please disclose the source for your data related to the current standard of care screening tests.
No reply letter found.
Please expand on your statement that "[t]he low input requirements support retrospective research studies" to explain what a low input requirement means in this context and how it supports retrospective research studies.
No reply letter found.
We note your statement that you have "validated performance of our technology in an MRD setting, with sensitivity on par with tumor-informed methods." Please expand on this statement to note the measurement of sensitivity for both your technology and tumorinformed methods.
No reply letter found.
We note your disclosure that your population-scale studies involve partnerships with numerous leading academic and cancer institutions and large community networks. Throughout your discussion of each of your clinical trials, please identify the relevant partners, academic and cancer institutions, and community networks to which you refer.Rest of the question
Clarify who performed each of your studies and disclose whether any serious or unexpected adverse effects or other performance issues were identified. As a related matter, we note your statement that you "announced plans for a 100,000 individual real world study in the Medicare population." Here or elsewhere in the Information Statement, please expand on this statement to fully describe this planned study, including who is expected to perform the study and key inclusion criteria of the patients enrolled.
No reply letter found.
We note your statement that "[w]e have not used other samples to analyze or validate performance in an asymptomatic and intended use population to date, and thus we have not reported any interim findings or results from STRIVE." Please clarify why you have not reported any interim findings or results from STRIVE and how this relates to not using other samples to analyze or validate performance.
No reply letter found.
Please note when the SUMMIT and SYMPLIFY studies were initiated and when you completed enrollment for each study.
No reply letter found.
We note your disclosure that Madison is your sole supplier of tubes used for sample collection and Twist is the sole supplier of your DNA probes. Please file your supply agreements with Madison and Twist as exhibits to the Registration Statement or explain to us why you are not required to do so. Please refer to Item 601(b)(10)(ii)(B) of Regulation S-K.
No reply letter found.
With respect to your material patents, please disclose the specific products, product groups and technologies to which such patents relate, whether they are owned or licensed, the type of patent protection you have, the expiration dates, the applicable jurisdictions, and whether there are any contested proceedings or third-party claims.
No reply letter found.
We note your disclosure that "To the extent our products use the licensed technology, we are required to pay the Chinese University of Hong Kong low single-digit percentage royalties on net sales of such products," and that "[u]nder these license agreements, you are obligated to use specified efforts to reach milestones relating to the development and sale of products that use the Chinese University of Hong Kong'sRest of the question
technology, and our failure to do so could result in termination of the license agreements." Please note whether your existing products, including Galleri, your precision oncology portfolio, and DAC, use licensed technology such that you are required to pay the royalty on net sales of those products or if you reach certain milestones with respect to those products. If so, and to the extent material, please discuss these royalty payments and milestones in the Summary and Risk Factor sections of the Information Statement.
No reply letter found.
We reference your adjustment number (5) for "Non-recurring transaction related compensation." Please quantify the amount of the adjustment related to retention bonuses. Tell us how you determined it is appropriate to adjust for such payments in the determination of your non-GAAP measures and clarify how such compensation differs from other compensation paid to employees and management.Rest of the question
Refer to Question 100.01 of the Commission's Compliance and Disclosure Interpretation for Non-GAAP measures.
No reply letter found.
We note your statement that "Prior to the Spin-Off, we have had various other arrangements with Illumina, including arrangements whereby. . . in connection with Illumina’s acquisition of GRAIL in 2021, Illumina issued contingent value rights ("CVRs") representing the right to receive future cash payments on a quarterly basis representing a pro rata portion of certain GRAIL-related revenues." Please clarify to whomRest of the question
the CVRs were issued and if there will be any material obligations to make payments following the Spin-Off.
No reply letter found.
We see from page 176 that you recognized $15.7 million of development services revenue. Please tell us why you do not separately present the service revenue and related costs of revenues on the face of the statement of operations under Rule 5-03(b)(1)(a) of Regulation S-X.
No reply letter found.
We note your disclosure on page F-26 you use independent valuation experts and analyses to value the cash based equity awards. Please tell us the nature and extent of the valuation experts involvement and whether you believe the valuation expert was acting as an expert as defined under Section 11(a) of the Securities Act of 1933 and Section 436(b) of Regulation C, such that you must disclose the name of theRest of the question
valuation expert in the Form 10 along with a consent from the valuation expert once the Form 10 is publicly filed. If you conclude the valuation expert is not considered an expert under the Securities Act, please revise your filing to clarify.
No reply letter found.
We note your revised disclosure in response to previous comment 2 and re-issue the comment in part. If true, please clarify that Galleri's clinical validation is the view or belief of management based on the results of your clinical studies completed to date or otherwise revise your statement so that it is clear that the Galleri test has not been approved by the FDA or an equivalent foreign regulator.
No reply letter found.
We note your revised disclosure in response to comment 3. Please address the following: • You disclose that, based on data from your CCGA and PATHFINDER studies, Galleri "can predict with high accuracy (88%) the specific organ or tissue type where the cancer signal originated." Please revise your disclosure to disclose the data underlying your "88%" high accuracy rate, and briefly explain, as you do on page 127, howRest of the question
this measure relates to the PPVs of 43% and 44% noted on page 4 related to the same studies. • You disclose that "[a]pproximately 67% of cancer deaths result from cancers that have no recommended screening guidelines, based on our own estimates using 2022 American Cancer Society Facts and Figures." Please disclose the relevant "facts and figures" supporting your estimate. Make conforming changes throughout your filing where you cite to your estimates based on these facts and figures, including the description of your business on page 122 where you disclose that "we estimate that asymptomatic individuals undertaking a standard of care screening test are many times (2-24x depending on cancer type) more likely to have a different type of cancer than the cancer type for which they are being screened," and "single-cancer screening tests are also unlikely to be developed for detecting less common cancers." • We note your disclosure that "we estimate that adding Galleri to these five standard of care single-cancer screening tests (breast, cervical, colorectal, lung cancer, and prostate) could detect many more cancers at an earlier stage and potentially avert approximately 100,000 deaths per year in the United States as measured by five-year survival." Please provide the basis for your statement. • You disclose that "a recent analysis published in Data in September 2017 estimated that diagnosing cancer early could result in an estimated $26 billion in annual costsavings in the United States." Please identify the article or analysis. In addition, given your characterization of this statistic as "recent," please revise your disclosure to provide a more current source or tell us why you are unable to do so. • Your revised disclosure on page 5 includes a statement that "Data published in The Lancet Oncology showed that, in a symptomatic patient population, our methylation technology was able to detect many cancer types and identify where the cancer signal origin was located in the body with high accuracy (91%)." Please disclose the source of the data published in the Lancet and describe the data supporting the 91% accuracy rate. Generally, where you reference an article or analyses in a publication, please identify the specific article or analyses. For example, we note your disclosures on page 121 referencing "an article" in JAMA Oncology and "an article" in the Journal of the National Comprehensive Cancer Network.
No reply letter found.
We note your response and revised disclosure in response to previous comment 8 and reissue the comment in part. In addition to providing your anticipated timeline for launching the DAC test, please also describe the status of your development efforts.Rest of the question
To the extent you believe your other products in development are not currently material to your business, please include a statement to this effect in your disclosure or revise to remove statements that such future products present significant market opportunities.
No reply letter found.
Please briefly describe the difference between "PPV" and "modeled PPV," as it relates to your PATHFINDER and CCGA studies.
No reply letter found.
We note the statements in your response to previous comment 10 that "risks related to the regulatory proceedings are fundamentally borne by Illumina" and that "The Company expects that future costs associated with regulatory proceedings will be limited because the Separation and Distribution is anticipated to expedite resolution of these regulatory proceedings and the Company does not anticipate being a separateRest of the question
party to ongoing regulatory proceedings after the spin-off transaction." To provide investors with context about the potential regulatory risks to GRAIL, please include substantially similar statements in the Information Statement when discussing the regulatory proceedings. Risks Relating to Our Business and Industry We may be unable to develop and commercialize new products, including enhanced versions of current products., page 41
No reply letter found.
We note the statements including in your response letter in response to previous comment 11. Please include similar disclosure in the Information Statement when discussing potential enhanced versions of your products. Risks Relating to Regulation and Legal Compliance Our multi-cancer detection tests are a new approach to cancer screening, which present a number of novel and complex issues..., page 61
No reply letter found.
We note the statements included in your response to previous comment 12. Please include similar disclosure in the Information Statement when discussing your FDA submissions and FDA approval of your products. In this regard, we note that a portion of the risk factor addresses the risk that "it is difficult to predict what information [you] will need to submit to obtain approval of a PMA from the FDA for a proposedRest of the question
intended use." The additional details in your response letter provide helpful context in evaluating this risk. Given the potential importance of FDA approval of your products, this additional information should be included in your disclosure.
No reply letter found.
We note your response to comment 16, including that "outside advisors provided information and analyses to assist the Illumina Board, and the committee thereof, understand the range of potential divestment transactions, including regarding their respective structures, timing and process and legal considerations." Given that the information and analyses of the outside advisors appears to have aided the Illumina boardRest of the question
in its consideration of strategic alternatives and ultimate determination to effect the spinoff, please provide a more detailed legal analysis describing why the reports and recommendations provided by these outside advisors were not material to the board's decision. Alternatively, please revise your disclosure to identify the outside advisors and discuss the nature of the reports and recommendations provided by them to the Illumina board.
No reply letter found.
We note your revised disclosure and response to comment 17. We are considering your response and may have further comment. We will advise you once we have completed our consideration of this issue.
No reply letter found.
We note your response to comment 23 and your revised disclosure in the footnotes to the graphic on page 127. Given your disclosure that your graphic presents the PPVs and number of false positives associated with the "current" standard of care screening tests, please provide more current sources for your disclosure about the relevant data in the table, or tell us why you are unable to do so.Rest of the question
In this regard, we note that some of the sources in your footnotes are greater than five years old, and were published as early as 2009.
No reply letter found.
We note your response to comment 26, and your revised disclosure throughout this section listing "the name of certain larger partners involved in each of [y]our studies." Please expand your disclosure to include a brief description of the material terms of such collaborations, including whether you have funded or are funding any studies and research and if any compensation was involved.
No reply letter found.
We note your revised disclosure in response to comment 30. To the extent any individual patents in the patent families discussed are material to your business, please expand your disclosure to discuss the type of patent protection that the relevant issued patent(s) provide, the jurisdictions where the patent(s) have been issued, and the relevant expiration dates.Rest of the question
In addition, given the extent of the disclosure related to your patent families, please consider providing the disclosure in tabular form by patent family.
No reply letter found.
We note your response to previous comment 31 noting that the Company is currently paying royalties to CUHK on net sales across your Galleri, precision oncology and DAC products. Please reference the royalty payable to CUHK where you discuss the payment of other royalties in the Summary and Risk Factor sections or explain to us why you do not view this payment obligation as material.
No reply letter found.
We reference prior comment 32 in our letter dated January 8, 2024. Please further elaborate on the nature and terms of the retention bonuses provided in connection with the acquisition by Illumina, including a discussion of the term of the retention commitment, any additional services required to be provided by the employees above and beyond their normal employment and compared to employees in similar roles andRest of the question
responsibilities, and how the retention bonuses were calculated. Please note that under Question 100.01 of the Non-GAAP Financial Measures Compliance & Disclosure Interpretations, it is generally not appropriate to adjust GAAP measures for costs that relate to revenue generating activities.
No reply letter found.
Please revise to provide all of the information required by Item 401(e) of Regulation S-K. For example, revise to describe the business experience, principal occupations and employment of your officers over the last five years, including the dates and duration of employment.
No reply letter found.
We note your responses to comments 1 and 2, and reissue these comments in part. In this regard, please revise your summary so that it is clear and prominent to investors that you do not produce or market a diagnostic test, but rather, a cancer screening test, and that this test has not been approved by the FDA.Rest of the question
Please also make it clear and prominent that your future business and commercialization plans include FDA approval. In your revised disclosure, please address the following comments: • At first instance, where you disclose that you believe Galleri is clinically validated, please revise your disclosure to make it clear that the Galleri test has not been approved by the FDA or an equivalent foreign regulator, and that the Galleri test has been validated as a screening test rather than a diagnostic test. In this regard, where you discuss "detection" by Galleri, please ensure that it is clear that this detection required additional diagnostic testing. • Where you make claims about the accuracy of your Galleri test, including at first instance, please provide data to support your claims, or include a cross reference to the data elsewhere in your filing. Please also clarify that "accuracy" in this context does not mean that the Galleri test itself was used to provide a cancer diagnosis. In addition, please provide additional context for your statement that "we estimate that by adding Galleri to the five standard of care single-cancer screening tests (breast, cervical, colorectal, lung cancer, and prostate), there is potential to detect many more cancers at an earlier stage, which could translate into the potential to avert approximately 100,000 deaths per year in the United States as measured by five-year survival, or 39% of the five-year deaths expected if not for early detection by Galleri," including that there is no guarantee Galleri will be added to the current standard of care screening.
No reply letter found.
We note your response to comment 3 and your revised disclosure that your DAC test is a "mediumto longer-term objective." Please revise your disclosure to provide an estimated timeframe for "mediumto longer-term." Risks Relating to Our Business and Industry We may be unable to develop and commercialize new products, including enhanced versions of current products., page 41
No reply letter found.
We note your revised disclosure in response to previous comment 6 regarding bridging studies for new or enhanced versions of your current products and re-issue the comment in part. Your response to comment 11 from our January 8, 2024 comment letter, included in your January 29, 2024 response letter: • noted that "in the near term, enhancements are focused on improvements to Galleri and, in particular, on automation,Rest of the question
panel size, and other scaling improvements and updates to the machine-learning classifier" and that "[f]uture enhancements may also include a reduction in panel size to enable additional scaling, as well as further training of the classifier on additional data for potential future improvement;" • in addition to bridging studies, discussed the need to conduct "a non-inferiority study compared to the relevant current version of Galleri using clinical study and real world evidence data (obtained through Galleri’s current commercial use as an LDT);" • explained that because of the bridging study, "the Company does not believe the changes will impact the Company’s ability to rely on previously-collected data generated from earlier versions of the Company’s products;" and • also noted that "[a]s a contingency plan, if non-inferiority or non-concordance cannot be established, the Company can revert to the prior classifier and version of the test used in the existing version of Galleri." Please include similar disclosure in the Information Statement when discussing potential enhanced versions of your products, or otherwise briefly explain what changes or improvements you expect to make to the enhanced versions of your current products, and if you believe these changes will impact your ability to rely on previously-collected data on earlier versions of your products in connection with your submission for marketing authorization (or certification) of your products. Risks Relating to Regulation and Legal Compliance Our multi-cancer detection tests are a new approach to cancer screening, which present a number of novel and complex issues..., page 61
No reply letter found.
We note your revised disclosure in response to previous comment 7 and re-issue the comment in part. In your January 29, 2024 response letter, you noted that "following several pre-submissions to the FDA regarding the Company’s proposed clinical studies, and a meeting with the FDA in June 2023, the Company received feedback on several aspects of the clinical validation pathway for Galleri PMA.Rest of the question
First, the FDA will permit the number of cancer-type specific clinical samples required for the Company’s proposed cancer type claims to be based on the prevalence of each particular cancer type in the intended use population. Second, the FDA will not require the Company to perform a head-to-head comparison of Galleri and standard of care screening methods as a prerequisite for PMA approval, and will instead address such comparative data as part of labelling or at a later date. Third, the FDA will permit GRAIL to return results to ordering providers on any cancer signal of origin detected by Galleri, regardless of whether GRAIL has sufficient clinical evidence for an affirmative claim for that cancer type." Please include this information in your disclosure as it provides important context to the risk that it is difficult to predict what information you will need to submit to obtain approval of a PMA from the FDA. Alternatively, please advise us why you do not believe this information is material or should be disclosed in the Information Statement. Reasons for the Spin-Off, page 100
No reply letter found.
We note the removal of references to outside advisors from the Information Statement in response to previous comment 8 and re-issue the comment in part. With respect to any information and analyses from outside advisors that the Illumina board has already received and that have aided the board in its consideration of strategic alternatives, please provide a more detailed legal analysis describing why the reports andRest of the question
recommendations provided by these outside advisors are not material to the board’s decision. If the board is still evaluating potential divestment transactions and has not made a final determination to move forward with the Spin-Off, please note this in your next response letter and provide any materiality analysis in the context of the board's ultimate decision once known. To the extent that the board receives additional information and analyses from outside advisors in connection with its evaluation of the Spin-Off, including with respect to any final determination to move forward with the Spin-Off rather than any of the other potential divestment transactions, please include disclosure regarding the third party advisors and their recommendations in a subsequent amendment or provide us with a legal analysis describing why this information is not material.
No reply letter found.
We note your revised disclosure that you expect your research and development expenses to plateau over the coming years as your existing clinical studies and development of your automated platform conclude. Please revise your disclosure to provide an estimated timeframe for "the coming years."
No reply letter found.
We note your disclosure that "[i]n the third quarter of 2023, we concluded the sustained decrease in Illumina’s stock price and overall market capitalization during the quarter was a triggering event indicating the fair value of GRAIL might be less than its carrying amount that led us to test goodwill for impairment," and "[w]e recognized an additional goodwill impairment of $608.5 million in 2023 primarily due toRest of the question
changes to expected timing of revenue and a higher discount rate." Please revise your filing to provide a risk factor discussing the risks associated with this impairment and possible future impairments or explain why you do not believe a risk factor is warranted.
No reply letter found.
We reference the 90% increase in revenue from fiscal year 2022 to fiscal year 2023. Please revise to provide greater insight into the contributors to the significant increase in revenue, including the underlying reasons for the increase in Galleri sales volume. Reference Item 303(a)-(b) of Regulation S-K and the three principal objectives of MD&A, as noted in SEC Release No. 33-8350.
No reply letter found.
We note your disclosure that "[t]he increase in development services revenue of $2.4 million was primarily due to new pilots initiated with biopharmaceutical partners in fiscal year 2023." In an appropriate place in your filing, please describe the terms of these pilots with biopharmaceutical partners, if material.
No reply letter found.
We note your response to comment 14. You state that the bonuses were allocated amongst all employees in good standing below the executive leadership team level and that no additional services were required to be provided by the employees above and beyond their normal employment compared to other similar roles and responsibilities.Rest of the question
Therefore, it appears that these costs represent cash compensation, which is a normal, recurring operating expense. As such, we request that you discontinue including this adjustment in your non-GAAP measures for any period presented in accordance with Rule 100(b) of Regulation G as interpreted by Question 100.01 of the Non-GAAP Financial Measures Compliance & Disclosure Interpretations, as updated December 13, 2022.
No reply letter found.
We reissue prior comment 10. Based on your response, the transaction related compensation and payroll taxes appear to be normal, recurring operating expense since the underlying services performed by your employees were consistent with their normal roles and responsibilities.Rest of the question
As such, we request that you discontinue including this adjustment in your non-GAAP measures for any period presented in accordance with Rule 100(b) of Regulation G as interpreted by Question 100.01 of the Non-GAAP Financial Measures Compliance & Disclosure Interpretations, as updated December 13, 2022.
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on pages 185 and 202 of the FormRead in the reply
10 accordingly.
* * *
We hope the foregoing answers are responsive to your comments. Please do not hesitate to contact me by telephone at (714) 755-8051 with any questions or comments regarding this correspondence.
Revise your disclosure here and in your description of business to provide support for your statement that cancer "can be cured," and provide additional context for how this statement relates to the cancers detected by your Galleri test, given your disclosure that "Galleri demonstrated an ability to detect a shared cancer signal across more than 50 types of cancer." Alternatively, please remove this disclosure fromRest of the question
your filing. Background
TheRead in the reply
Company respectfully acknowledges the Staff’s comment and has revised the disclosure on pages 3, 126, 132 and 168 of Amendment No. 1 accordingly. The Company respectfully notes that the reference to cancer being “cured” is based on general terminology and usage in the industry and medical fields. For example, according to an article published in Science (Science. (2020) 368:589–90), “[a] tumor that has not metastasized at the time of diagnosis can be completely removed and cured by surgery.Rest of the answer
A tumor that has metastasized may also be curable by a combination of surgery and systemic therapy, but some will be incurable.” In addition, according to the American Cancer Society’s webpage titled Can Cancer Be Cured1, “[w]hether a person’s cancer can be cured depends on the type and stage of the cancer, the type of treatment they can get, and other factors. Some cancers are more likely to be cured than others. But each cancer needs to be treated differently. There isn’t one cure for cancer.” Further, the World Health Organization’s fact sheet on cancer2 notes that “[t]he primary goal [of treatment] is generally to cure cancer or to considerably prolong life” and that “[m]any cancers can be cured if detected early and treated effectively.” The World Health Organization also refers to multiple cancers, including breast cancer, cervical cancer, oral cancer and colorectal cancer, as having “high cure probabilities when detected early and treated according to best practices.” The Company respectfully submits that its general references to “cured” in the context in which this word is used in the Form 10 is aligned with these examples and general usage of the term in publications and other sources.
The Company also notes that the context in which “cured” is used is limited and specific to the Company’s mission statement (“Our mission is to detect cancer early, when it can be cured.”), which the Company believes is important to an understanding of the Company. The Company respectfully submits that this mission statement is aspirational in nature, represents an expression of the Company’s overall philosophy and culture to improve cancer care and drive to improve better outcomes for cancer patients.
https://www.cancer.org/cancer/understanding-cancer/can-cancer-be-cured.html
. Accessed May 24, 2024.
https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed May 24, 2024.
We note that you have removed disclosure that you "do not anticipate being a separate party to ongoing regulatory proceedings after the Spin-Off." If this removal means that you will be a separate party to ongoing regulatory proceedings after the Spin-Off, please revise your summary and risk factors to disclose this fact and to describe the related risks. Disposal Funding, page 230
TheRead in the reply
Company respectfully acknowledges the Staff’s comment and has revised the disclosure on pages 57, 58 and 103 of Amendment No. 1 accordingly. The Company respectfully notes that, as certain procedures and proceedings will continue after the
Spin-Off, it will be a separate party to a number of administrative and litigation proceedings, and the Company has revised the disclosure to clarify the extent of such involvement.
We note your disclosure that "[u]nder certain circumstances, we will be required to return a portion of the Disposal Funding to Illumina in the event we make a dividend payment or share repurchase or experience a change of control." Please revise to provide additional detail describing the "certain circumstances," including the portion of the Disposal Funding you will be required to return to Illumina.
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure on page 234 of the Form 10 Amendment No. 1 accordingly.Read in the reply
We note your reference in Exhibit 2.1 to a PIPE and PIPE Commitments. Please revise your filing to disclose whether you have entered into or have plans to enter into a PIPE, the material terms of any such PIPE, and file any PIPE agreement(s) as an exhibit to your registration statement.
The Company acknowledges the Staff’s comment and respectfully advises the Staff that it has not entered into and does not have any plans to enter into a PIPE. Accordingly, the Company has revised the disclosure on pages ii, 3, 5, 7, 10 and 11 of Exhibit 2.1.Read in the reply
* * *
We hope the foregoing answers are responsive to your comments. Please do not hesitate to contact me by telephone at (714) 755-8051 with any questions or comments regarding this correspondence.